{"id":"https://openalex.org/W4400108759","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586","title":"Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.","display_name":"Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4400108759","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.4586","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075438799","display_name":"Jacqueline Theresa Brown","orcid":"https://orcid.org/0000-0002-1885-0906","observed_orcids":["https://orcid.org/0000-0002-1885-0906"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline T. Brown","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086546163","display_name":"Bassel Nazha","orcid":"https://orcid.org/0000-0001-6385-1329","observed_orcids":["https://orcid.org/0000-0001-6385-1329"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bassel Nazha","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100390808","display_name":"Yuan Liu","orcid":"https://orcid.org/0000-0001-6227-024X","observed_orcids":["https://orcid.org/0000-0001-6227-024X"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuan Liu","raw_affiliation_strings":["Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kelsea Lozada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelsea Lozada","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112370417","display_name":"Jeremy D. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy D. Smith","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108940157","display_name":"Caitlin Hartman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caitlin Hartman","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018821925","display_name":"Greta Russler McClintock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greta Russler McClintock","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Omer Kucuk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omer Kucuk","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035665916","display_name":"Bradley Curtis Carthon","orcid":"https://orcid.org/0000-0002-9176-8538","observed_orcids":["https://orcid.org/0000-0002-9176-8538"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bradley Curtis Carthon","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043235685","display_name":"Robert Donald Harvey","orcid":"https://orcid.org/0000-0002-4217-1313","observed_orcids":["https://orcid.org/0000-0002-4217-1313"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Donald Harvey","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049071296","display_name":"Mehmet As\u0131m Bilen","orcid":"https://orcid.org/0000-0003-4003-1103","observed_orcids":["https://orcid.org/0000-0003-4003-1103"]},"institutions":[{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehmet Asim Bilen","raw_affiliation_strings":["Winship Cancer Institute of Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute of Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I4390039307"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"4586","last_page":"4586"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-urothelial-carcinoma","display_name":"metastatic urothelial carcinoma","score":0.921999990940094},{"id":"https://openalex.org/keywords/enfortumab-vedotin","display_name":"enfortumab vedotin","score":1.0},{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.921999990940094},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/nectin-4","display_name":"nectin-4","score":0.9129999876022339},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7279999852180481},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6510000228881836},{"id":"https://openalex.org/keywords/dose-expansion","display_name":"dose expansion","score":0.5910000205039978},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7689999938011169},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.859000027179718},{"id":"https://openalex.org/keywords/platinum-ineligible-patients","display_name":"platinum-ineligible patients","score":0.5529999732971191},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.5809999704360962},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.31700000166893005}],"concepts":[{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.9409788846969604},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8794235587120056},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6728073954582214},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.6176488995552063},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.6174362897872925},{"id":"https://openalex.org/C2776957806","wikidata":"https://www.wikidata.org/wiki/Q4895105","display_name":"Interim","level":2,"score":0.5876916646957397},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5760214924812317},{"id":"https://openalex.org/C3020745361","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial cancer","level":4,"score":0.5093399286270142},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.4463613033294678},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.34570491313934326},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33761757612228394},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3344760835170746},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.25242167711257935},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.16249066591262817},{"id":"https://openalex.org/C166957645","wikidata":"https://www.wikidata.org/wiki/Q23498","display_name":"Archaeology","level":1,"score":0.0},{"id":"https://openalex.org/C95457728","wikidata":"https://www.wikidata.org/wiki/Q309","display_name":"History","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.4586","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.4586","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391333788","https://openalex.org/W4386699977","https://openalex.org/W2891866600","https://openalex.org/W3089145843","https://openalex.org/W3008618884","https://openalex.org/W7214186683","https://openalex.org/W2922015761","https://openalex.org/W7162536383","https://openalex.org/W3049165301","https://openalex.org/W3172466890"],"abstract_inverted_index":{"4586":[0],"Background:":[1],"Despite":[2],"recent":[3],"advances,":[4],"metastatic":[5],"urothelial":[6],"carcinoma":[7],"(mUC)":[8],"remains":[9,361],"a":[10,41,113,144,174,313,382,464],"deadly":[11],"disease.":[12],"Enfortumab":[13],"vedotin":[14],"(EV)":[15],"is":[16,40,112,203,213,249,369,392,415],"an":[17,94,398,420],"antibody-drug":[18],"conjugate":[19],"(ADC)":[20],"specific":[21],"for":[22,140,189],"Nectin-4":[23],"approved":[24],"in":[25,29,35,55,101,105,177,264,276,402],"combination":[26,102,410],"with":[27,53,103,108,131,161,339,353,419,424,428,446],"pembrolizumab":[28],"1L":[30],"treatment":[31],"and":[32,51,79,87,143,171,192,205,246,267,279,303,326,344,360,377,384,400,413,417,452,458],"as":[33,185],"monotherapy":[34],"later-line":[36],"therapy.":[37],"Cabozantinib":[38],"(cabo)":[39],"multi-tyrosine":[42],"kinase":[43],"inhibitor":[44,146],"(TKI)":[45],"that":[46,408,425],"inhibits":[47],"VEGF":[48],"1-3,":[49],"MET":[50],"AXL":[52],"activity":[54,435],"heavily":[56],"pretreated":[57],"mUC.":[58,109,403],"Preclinical":[59],"data":[60,82,233,406],"suggests":[61],"antiangiogenic":[62],"agents":[63],"may":[64],"increase":[65],"ADC":[66,399],"penetration":[67],"of":[68,93,126,173,207,216,228,411,434,440],"tumor":[69],"cells,":[70],"potentially":[71],"leading":[72],"to":[73,198,358],"therapeutic":[74],"synergy.":[75],"We":[76],"report":[77],"safety":[78,204],"preliminary":[80,214,405],"efficacy":[81,217],"from":[83],"the":[84,122,186,208,229,257,319,331,335,347,393,409],"dose":[85,90,152,163,188,190,262,265,277,386,444],"escalation":[86,153,266,278],"currently":[88],"accruing":[89],"expansion":[91,191,281,445],"cohort":[92],"ongoing":[95],"phase":[96,114,150],"I/Ib":[97],"trial":[98,120,396,468],"investigating":[99],"cabo":[100,155,258,272,374,378,414,447],"EV":[104,164,412],"patients":[106,194],"(pts)":[107],"Methods:":[110],"This":[111,391],"I/Ib,":[115],"open":[116],"label,":[117],"single":[118],"arm":[119],"at":[121,256,463],"Winship":[123],"Cancer":[124],"Institute":[125],"Emory":[127],"University":[128],"(NCT04878029).":[129],"Pts":[130,372],"histologically":[132],"confirmed":[133],"mUC":[134,441],"who":[135],"received":[136,271],"or":[137,157],"were":[138,254,322],"ineligible":[139],"platinum":[141],"chemotherapy":[142],"checkpoint":[145],"are":[147,241,244,288],"eligible.":[148],"The":[149,200,283,364],"I":[151],"explored":[154],"20":[156,181,273,379,448],"40":[158,259,375],"mg":[159,182,260,274,376,380,449],"daily":[160,261,275,450],"standard":[162],"(1.25":[165],"mg/kg":[166],"on":[167,362,373],"days":[168],"1,":[169],"8,":[170],"15":[172],"28-day":[175],"cycle)":[176],"6":[178,230],"patients.":[179],"Cabo":[180],"was":[183,337],"chosen":[184],"recommended":[187],"4":[193],"have":[195,237,270,381],"been":[196,238,437],"treated":[197],"date.":[199,466],"primary":[201],"endpoint":[202],"tolerability":[206],"combination.":[209],"Key":[210],"secondary":[211],"objective":[212,219],"evidence":[215,433],"via":[218],"response":[220],"rate":[221],"(ORR)":[222],"per":[223],"RECIST":[224],"v1.1.":[225],"Results:":[226],"As":[227],"January":[231],"2024":[232],"cut,":[234],"10":[235],"pts":[236,253,269,310,442],"treated.":[239],"All":[240],"male,":[242],"80%":[243],"white,":[245],"median":[247,365],"age":[248],"67.3":[250],"(49-85).":[251],"Four":[252],"enrolled":[255],"level":[263],"six":[268],"then":[280],"cohorts.":[282],"most":[284,320],"common":[285,321],"treatment-related":[286,317],"AEs":[287],"fatigue":[289,327],"(55.6%),":[290],"skin":[291],"rash,":[292],"hand-foot":[293],"syndrome,":[294],"anorexia":[295],"(all":[296,307,328],"44.4%),":[297],"hyponatremia,":[298,324],"hypophosphatemia,":[299],"mucositis,":[300],"ALT":[301],"elevation,":[302],"peripheral":[304],"sensory":[305],"neuropathy":[306],"33.3%).":[308],"Eight":[309],"(88.9%)":[311],"had":[312],"grade":[314],"\u2265":[315],"3":[316],"AE;":[318],"neutropenia,":[323],"AKI":[325],"22.2%).":[329],"Of":[330],"9":[332],"response-evaluable":[333],"pts,":[334],"ORR":[336],"88.9%":[338],"7":[340],"responders":[341],"achieving":[342],"PR":[343],"1":[345,349],"CR;":[346],"remaining":[348],"pt":[350],"achieved":[351],"SD":[352],"18.94%":[354],"target":[355,366],"lesion":[356,367],"reduction":[357,368,387],"date":[359],"trial.":[363],"52.51%":[370],"(18.94-100).":[371],"100%":[383],"60%":[385],"rate,":[388],"respectively.":[389],"Conclusions:":[390],"first":[394],"clinical":[395],"combining":[397],"TKI":[401],"These":[404],"suggest":[407],"safe":[416],"tolerable":[418],"AE":[421],"profile":[422],"consistent":[423],"previously":[426],"seen":[427],"each":[429],"agent.":[430],"Encouraging":[431],"early":[432],"has":[436],"observed.":[438],"Enrollment":[439],"into":[443],"continues":[451],"further":[453],"results":[454],"including":[455],"long-term":[456],"outcomes":[457],"correlatives":[459],"will":[460],"be":[461],"reported":[462],"later":[465],"Clinical":[467],"information:":[469],"NCT04878029":[470],".":[471]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-06-29T00:00:00"}